Cargando…
Bladder Cancer Immunotherapy: BCG and Beyond
Mycobacterium bovis bacillus Calmette-Guérin (BCG) has become the predominant conservative treatment for nonmuscle invasive bladder cancer. Its mechanism of action continues to be defined but has been shown to involve a T helper type 1 (Th1) immunomodulatory response. While BCG treatment is the curr...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388311/ https://www.ncbi.nlm.nih.gov/pubmed/22778725 http://dx.doi.org/10.1155/2012/181987 |
_version_ | 1782237168229416960 |
---|---|
author | Askeland, Eric J. Newton, Mark R. O'Donnell, Michael A. Luo, Yi |
author_facet | Askeland, Eric J. Newton, Mark R. O'Donnell, Michael A. Luo, Yi |
author_sort | Askeland, Eric J. |
collection | PubMed |
description | Mycobacterium bovis bacillus Calmette-Guérin (BCG) has become the predominant conservative treatment for nonmuscle invasive bladder cancer. Its mechanism of action continues to be defined but has been shown to involve a T helper type 1 (Th1) immunomodulatory response. While BCG treatment is the current standard of care, a significant proportion of patients fails or do not tolerate treatment. Therefore, many efforts have been made to identify other intravesical and immunomodulating therapeutics to use alone or in conjunction with BCG. This paper reviews the progress of basic science and clinical experience with several immunotherapeutic agents including IFN-α, IL-2, IL-12, and IL-10. |
format | Online Article Text |
id | pubmed-3388311 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-33883112012-07-09 Bladder Cancer Immunotherapy: BCG and Beyond Askeland, Eric J. Newton, Mark R. O'Donnell, Michael A. Luo, Yi Adv Urol Review Article Mycobacterium bovis bacillus Calmette-Guérin (BCG) has become the predominant conservative treatment for nonmuscle invasive bladder cancer. Its mechanism of action continues to be defined but has been shown to involve a T helper type 1 (Th1) immunomodulatory response. While BCG treatment is the current standard of care, a significant proportion of patients fails or do not tolerate treatment. Therefore, many efforts have been made to identify other intravesical and immunomodulating therapeutics to use alone or in conjunction with BCG. This paper reviews the progress of basic science and clinical experience with several immunotherapeutic agents including IFN-α, IL-2, IL-12, and IL-10. Hindawi Publishing Corporation 2012 2012-06-20 /pmc/articles/PMC3388311/ /pubmed/22778725 http://dx.doi.org/10.1155/2012/181987 Text en Copyright © 2012 Eric J. Askeland et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Askeland, Eric J. Newton, Mark R. O'Donnell, Michael A. Luo, Yi Bladder Cancer Immunotherapy: BCG and Beyond |
title | Bladder Cancer Immunotherapy: BCG and Beyond |
title_full | Bladder Cancer Immunotherapy: BCG and Beyond |
title_fullStr | Bladder Cancer Immunotherapy: BCG and Beyond |
title_full_unstemmed | Bladder Cancer Immunotherapy: BCG and Beyond |
title_short | Bladder Cancer Immunotherapy: BCG and Beyond |
title_sort | bladder cancer immunotherapy: bcg and beyond |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388311/ https://www.ncbi.nlm.nih.gov/pubmed/22778725 http://dx.doi.org/10.1155/2012/181987 |
work_keys_str_mv | AT askelandericj bladdercancerimmunotherapybcgandbeyond AT newtonmarkr bladdercancerimmunotherapybcgandbeyond AT odonnellmichaela bladdercancerimmunotherapybcgandbeyond AT luoyi bladdercancerimmunotherapybcgandbeyond |